Form 4: Glaukos Corp Executive Alex R. Thurman Acquires 7,320 Shares Via Stock Option Vesting

Alex R. Thurman, SVP & CFO of Glaukos Corporation, acquired 7,320 shares of common stock through the vesting of a stock option related to the achievement of pre-determined operational targets.

Summary

• On September 19, 2024, Alex R. Thurman, the SVP & CFO of Glaukos Corporation, acquired 7,320 shares of Glaukos Corp [GKOS] common stock.
• This acquisition resulted from the vesting of a stock option previously granted on March 24, 2022.
• The vesting was contingent upon Glaukos achieving certain operational targets over a multi-year period.
• The Compensation, Nominating and Governance Committee determined on September 19, 2024, that these targets had been met.
• The exercise price of the stock option is $55.18.
• Following the transaction, Thurman directly owns 30,192 shares.
• The acquired shares will vest in four tranches: September 2024, December 2024, May 2025, and September 2025.

Sentiment

Score: 7

Explanation: The document indicates that the company has achieved certain operational targets, which is a positive sign. The executive's increased stake in the company also aligns his interests with those of the shareholders. However, it is a routine filing related to executive compensation.

Positives

• The vesting of the stock option indicates that Glaukos Corporation has achieved certain operational targets, which is a positive sign for the company's performance.
• The executive's increased stake in the company aligns his interests with those of the shareholders.

Future Outlook

The acquired shares will vest in four tranches: September 2024, December 2024, May 2025, and September 2025.

Management Comments

• The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on September 19, 2024 that certain of the operational targets had been achieved.

Industry Context

Executive stock option grants and vesting are common practices in publicly traded companies to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical and medical device industries, similar to companies like Alcon or Johnson & Johnson's medical device segment.
• Vesting schedules tied to performance metrics are also common, ensuring that executives are rewarded for achieving specific company goals, similar to performance-based equity awards at Medtronic or Stryker.

Stakeholder Impact

• Shareholders may view the vesting of stock options as a positive sign, indicating that the company is achieving its operational goals.
• Employees may be motivated by the company's success in meeting its targets.

Key Dates